Open AccessThe Effects of Cinacalcet in Older and Younger Patients on Hemodialysis
Author(s) -
Patrick S. Parfrey,
Tilman B. Drüeke,
Geoffrey A. Block,
Ricardo CorreaRotter,
Jürgen Floege,
Charles A. Herzog,
Gérard M. London,
Kenneth W. Mahaffey,
Sharon M. Moe,
David C. Wheeler,
Yumi Kubo,
Bastian Dehmel,
William G. Goodman,
Glenn M. Chertow
Publication year - 2015
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.07730814
Subject(s) - cinacalcet , medicine , hazard ratio , calcimimetic , hemodialysis , placebo , secondary hyperparathyroidism , parathyroidectomy , randomized controlled trial , relative risk , kidney transplantation , comorbidity , transplantation , confidence interval , surgery , parathyroid hormone , alternative medicine , pathology , calcium
The calcimimetic cinacalcet reduced the risk of death or cardiovascular (CV) events in older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation, parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older (≥65 years, n=1005) and younger (<65 years, n=2878) patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom